Morgan Stanley Lowers Biogen (BIIB) Price Target to $366.00


The brokerage currently has an "overweight" rating on the biotechnology company's stock. Morgan Stanley's target price would indicate a potential upside of 5.03% from the stock's current price.



from Biotech News